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Abstract 
Human endogenous retroviruses (HERVs) have been shown to be important in physiological and 
pathophysiological processes in humans. Several HERVs have been found to be expressed in the 
placenta—a tissue with special immunomodulatory functions that is responsible for nutrition of the 
embryo and the ability of the semiallogenic trophoblast to invade. The envelope proteins of HERV-W 
(also known as syncytin 1) and HERV-FRD (syncytin 2) were shown to be involved in cell fusion 
leading to the generation of the syncytiotrophoblast. Syncytin 2 was further shown to have 
immunosuppressive properties. Herein we analyse the expression of another HERV, HERV-K, which 
is characterised by open reading frames for all viral genes. Using immunohistochemistry and Western 
blot analysis, expression of the transmembrane envelope (TM) protein of HERV-K was studied in 
normal placental and decidual tissues obtained at different gestational ages. The TM protein was 
expressed exclusively in villous (VT) and extravillous cytotrophoblast (EVT) cells, but not in the 
syncytiotrophoblast or other cells. The expression of the TM protein of HERV-K in EVT cells was 
confirmed by Western blot analysis of isolated c-erbB2-expressing cytotrophoblast cells. Thus, this is 
the first report showing expression of the TM protein of HERV-K in normal human placental tissue with 
an exclusive expression in cytotrophoblast cells, suggesting a potential involvement of HERV-K in 
placentogenesis and pregnancy. Since retroviral TM proteins including the TM protein of HERV-K 
have immunosuppressive properties, expression of the TM protein of HERV-K may contribute to 




In the last few years our knowledge of the role of endogenous retrovirus-like sequences that account 
for approximately 8% of the human genome in physiological and pathophysiological processes 
increased rapidly (for review see [Boeke and Stoye, 1997] and [Denner, 2010]). Many of the human 
endogenous retroviruses (HERVs) were found to be expressed in different tissues, including the 
placenta. Most of the HERVs are defective; however, some, such as HERV-K, have retained open 
reading frames for all viral proteins (Löwer et al., 1996) or at least for the functional envelope protein  
([de Parseval et al., 2003] and [Dewannieux et al., 2005]). Different genes of HERV-K such as the gag 
gene, encoding for the core proteins, the pol gene encoding for the reverse transcriptase converting 
the genomic RNA into proviral DNA, and the env gene, encoding the envelope proteins involved in 
receptor recognition and membrane fusion, as well as the accessory proteins Rec and Np9 (Löwer et 
al., 1993), are expressed in germ cell tumours ( [Löwer et al., 1996] and [Götzinger et al., 1996]) and 
melanomas ( [Muster et al., 2003], [Büscher et al., 2005] and [Büscher et al., 2006]). There are several 
indications that Rec and Np9 may be involved in tumour induction ( [Boese et al., 2000], [Armbruester 
et al., 2002] and [Galli et al., 2005]). 
In order to establish a normal pregnancy, proper implantation needs to be tightly regulated by specific 
cells expressed on the feto-maternal interface. The placenta is made up of chorionic villi covered by a 
double layer of trophoblast cells. The outer syncytiotrophoblast is formed by fusion of underlying 
mononuclear cytotrophoblast cells, called villous cytotrophoblast (VT) cells. At the distal end of the 
chorionic villi, some of the VT cells grow through the syncytial layer to form columns of extravillous 
  
cytotrophoblast (EVT) cells that invade into the maternal decidua (Burrows et al., 1996). These EVT 





natural killer and other immune cells that are known to control trophoblast invasion (Bulla et al., 2004). 
The function of the syncytiotrophoblast on the other hand is to produce hormones and to supply the 
fetal cells with nutrients (Desforges and Sibley, 2010). 
The placenta is a preferential site of expression of different HERV, with HERV-W (syncytin-1) ( [Blond 
et al., 1999], [Blond et al., 2000], [Mi et al., 2000] and [Kim et al., 2008]), and HERV-FRD (syncytin-2) 
(Malassiné et al., 2005) as first examples of an “enslavement” of endogenous retroviral genes in the 
reproductive tract of the host. In addition, ERV-3 ( [Boyd et al., 1993] and [Venables et al., 1995]) and 
HERV-E (Yi and Kim, 2007) were also found to be expressed in placental tissue. While syncytin-1 
interacts with the D type mammalian retrovirus receptor (ASCT2) ( [Blond et al., 2000] and [Lavillette 
et al., 2002]), which is mainly expressed in VT cells (Hayward et al., 2007), the receptor of syncytin-2 
(MFSD2) is specifically expressed in the syncytiotrophoblast (Esnault et al., 2008). Syncytin-1 was 
shown to mediate the fusion of the villous cytotrophoblast to form the multinucleated 
syncytiotrophoblast ( [Blond et al., 2000] and [Frendo et al., 2003]). Syncytin-1 and syncytin-2 differ in 
their site of expression within the normal placenta with syncytin-1 localised in both VT and EVT cells 
(Muir et al., 2006) and syncytin-2 expressed only in VT cells (Malassiné et al., 2007). Syncytin-1 and 
syncytin-2 are abnormally expressed under pathological conditions, supporting their relevance in 
reproduction. In preeclampsia, for example, a pathological trophoblast invasion into the maternal 
decidua, syncytin-1 is localised in the apical rather than the basal aspect of the syncytiotrophoblast  
([Lee et al., 2001] and [Knerr et al., 2002]). Nevertheless, it remains unclear whether this observation 
reflects the cause or the effect of the placental abnormality. Syncytin-2 expression, on the other hand, 
is altered in placentas of women with trisomy 21, where fusion of VT and maturation of chorionic villi is 
delayed ( [Malassiné et al., 2008] and [Malassiné et al., 2010]). 
In addition to the fusogenic property of the retroviral envelope proteins, the retroviral TM proteins are 
characterised by immunosuppressive properties that may be involved in the pathogenesis of 
retrovirus-induced immunodeficiency (for review see [Denner, 2000] and [Denner, 2010]). It has been 
shown that syncytin-2 (the phylogenetically older), but not syncytin-1, is immunosuppressive and that 
its so-called immunosuppressive (isu) domain is responsible for the immunosuppressive effect 
(Mangeney et al., 2007). It was also shown that the TM protein and the isu-peptide of HERV-K inhibit 
proliferation of human peripheral mononuclear cells (PBMCs) and induce an increased release of IL6 
and IL10 as well as a decreased IL2 release (J. Denner, unpublished data). The TM protein of HERV-
K modulated the expression of more than 300 genes in PBMCs from healthy donors in the same way 
as the TM protein of the human immunodeficiency virus HIV-1 did (J. Denner, unpublished data). 
Herein, we investigate if and where HERV-K is expressed in normal placental tissue where it could be 
involved in the suppression of the maternal immune system. Therefore, the expression of the TM 
protein of HERV-K was studied in placentas of different gestational ages and in isolated EVT using 
immunohistochemistry and Western blot analysis with specific antibodies. 
 
2. Methods 
2.1. Tissue specimens and cell lines 
The studies were performed with the approval of the Ethics Committee of the Medical Faculty of the 
University of Würzburg. Placental and decidual tissues were obtained from 10 healthy women 
undergoing legal therapeutic abortions of an intact pregnancy at 6–12 weeks’ gestation, from two 
women undergoing legal abortion because of chromosomal aberration of the fetus at gestational week 
17 and of two cases of pregnancy failure at week 22. Three placentas each of gestational weeks 28, 
32 and 36 were collected at the time of a caesarean section carried out because of twin or triplet 
pregnancies. Three samples from gestational week 39 were obtained through elective caesarean 
section. Early pregnancy decidual tissue and placenta were obtained by suction curettage; decidual 
and placental tissue (villous trees) was dissected directly after delivery from placentas of gestational 
week 17 till term. Subsequently, tissue aliquots were either snap-frozen in liquid nitrogen and stored at 
−80 °C or fixed for 24 h in 4% PBS-buffered formalin. Two samples of decidua basalis of gestational 
weeks 8 and 10 were subjected to direct isolation of invasive cytotrophoblasts (EVT). Sections of 
  
frozen placental tissue samples were analysed after haematoxylin-eosin staining to detect samples 
without signs of necrosis and inflammation. Such samples were then used for protein isolation. 
Cell lines PA-1 (human teratocarcinoma), as well as the human choriocarcinoma JAR and JEG cell 
lines, were obtained from Cell line services (Heidelberg, Germany) and grown in RPMI-1640 medium 
supplemented with 10% fetal calf serum and gentamycin 25 μg/ml (all: PAA Laboratories GmbH, 
Cölbe, Germany) at 37 °C in 5% CO2. Human umbilical vein endothelial cells (HUVEC) were prepared 
freshly from cords corresponding to the gestational week 39 placentas following standard protocols 
(Baudin et al., 2007) and expanded in endothelial cell growth medium 2 (Promo Cell, Heidelberg, 
Germany). Cells were regularly split into new cell culture flasks and harvested for Western blot 
analysis using trypsin (PAA). 
 
2.2. Single cell isolation 
To isolate invasive cytotrophoblast (EVT) cells, fresh decidual tissue was cut into small pieces of 
approximately 1 mm
3
 with a mincing knife and digested for 20 min at 37 °C under slight agitation in 
PBS with 200 U/ml hyaluronidase (Sigma, Taufkirchen, Germany), 1 mg/ml collagenase type I 
(Seromed, Berlin, Germany), 0.2 mg/ml DNAse I (2500 U/mg; Sigma) and 1 mg/ml bovine serum 
albumin/fraction V (Sigma). The cell suspension was filtered through a sterile 50-μm stainless steel 
wire mesh and washed once in PBS. Mononuclear cells were then separated by a density gradient 
centrifugation (Leucocyte Separation Medium, PAA) and washed twice in PBS. Invasive EVT cells 
were characterised by expression of the human epidermal growth factor (EGF) receptor 2 (HER2/neu 
or ErbB2; Jokhi et al., 1994). Since EVT cells are the only cell type at the feto-maternal interface 
expressing ErB2, these cells were specifically isolated using anti-ErbB2 antibody coupled with 
microbeads (mouse IgG1; Miltenyi, Bergisch Gladbach, Germany) and a magnetic assisted cell-sorting 
(MACS) separator (Miltenyi). Purity of enriched EVT fraction was analysed by flow cytometry and in all 
cases >90% of the isolated cells were found to be positive for HLA-G (clone MEM-G9, Exbio, Biozol, 
Eching, Germany). Cells were subsequently used for protein isolation. 
 
2.3. HERV-K specific antibodies 
For immunohistochemistry and Western blot analysis, two HERV-K specific antibodies were used: 
Goat serum 26 was generated immunising a goat with the recombinant ectodomain of the TM protein 
of HERV-K ( [Büscher et al., 2005] and [Büscher et al., 2006]). A TM protein-specific polyclonal 
antibody preparation was purified by affinity chromatography using a column with recombinant TM 
protein of HERV-K. In addition, the mouse monoclonal antibody HERM-1811-5 specific for the HERV-
K TM protein was purchased from Austral Biologicals, San Ramon, CA, USA. The affinity-purified 
polyclonal antibody from goat serum 26 was used at 1:50 dilution for immunocytochemistry and at 
1:1000 for Western blot analysis. The HERM-1811-5 monoclonal antibody was diluted 1:200–1:500 
and 1:5000, respectively (Table 1). 
 
2.4. Epitope mapping 
Overlapping peptides corresponding to the ectodomain (aa465 to aa699) of the Env protein of HERV-
K (PubMed Accnr. Q69384) synthesised as a cellulose-adsorbed peptide spot library of 15-mer 
peptides overlapping by 13 amino acids (Jerini Biotools) were used. The affinity purified antibodies 
from goat serum 26 and the monoclonal HERM-1811-5 were incubated with the membrane for 3 h, 
washed three times for 15 min with Tris-buffered saline, pH 7.5 containing 0.1% Tween 20 (Sigma) 
and incubated for 2 h with the appropriate peroxidase-conjugated anti-goat secondary antibody diluted 
1:2000 (DAKO, Hamburg, Germany). Binding was detected using a chemiluminescence detection 






2.5. Western blot analysis 
For protein extraction, 2 × 10
6
 cells or 25 sections cut from frozen placenta (8 μm thick) were lysed in 
100 μl RIPA buffer (25 mM Tris/HCl pH 7.6; 150 mM NaCl; 1% NP-40; 1% Na-deoxycholate; 0.1% 
SDS), the total protein amount was quantified using the Bradford method and 100 μg of total protein 
per lane were resolved by 10% SDS-PAGE. After blotting onto nitrocellulose membrane and blocking 
with 5% non-fat dry milk in PBS, 0.05% (w/v) Tween 20, the membrane was incubated with the 
corresponding HERV-K-specific primary antibody at the appropriate dilution (Table 1) at 4 °C 
overnight, followed by incubation with horseradish peroxidase-coupled donkey anti-goat IgG (Santa 
Cruz, Heidelberg, Germany) diluted 1:2500, or goat anti-mouse IgG (KPL Medac, Wedel, Germany) 
diluted 1:7500, respectively. Detection was performed by a homemade ECL method. In brief, 50 mg of 
luminol sodium salt (Sigma) were dissolved in 200 ml 0.1 M Tris/HCl (pH 8.6) (ECL-solution A). For 
ECL-solution B, 11 mg of p-coumaric acid were dissolved in 10 ml of DMSO (both Sigma). Prior to the 
work, 3 ml of solution A were mixed with 0.3 ml of solution B and 0.9 μl of hydrogen peroxide, 30% 
(Merck, Darmstadt, Germany). Protein bands were visualised by autoradiography. 
 
2.6. Immunohistochemistry 
For immunohistochemical staining, 2- to 3-μm tissue sections were cut from paraffin-embedded tissue, 
placed onto APES (3-amino-propyltriethoxy-silane; Roth, Karlsruhe, Germany) coated slides, dewaxed 
in xylene, rehydrated in graded ethanol and distilled water. For antigen retrieval, sections were 
subjected to heat pretreatment by boiling in 0.01 M of sodium citrate buffer (pH 6.0) for 10 min in a 
microwave oven (600 W/s). Endogenous peroxidase was blocked by incubation in 0.1% hydrogen 
peroxide in PBS for 5 min. The slides were then incubated with the HERV-K specific primary 
antibodies diluted at optimised concentration (Table 1) in “antibody diluent” (Dako, Hamburg, 
Germany), washed in Tris-buffered saline (TBS; 25 mM Tris/HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl) 
followed by the “labelled streptavidin biotin” (LSAB+) anti-mouse/rabbit/goat detection system (Dako). 
DAB (Dako) was used as the chromogen and cells were counterstained with haematoxylin (Sigma). To 
identify invasive extravillous EVT a monoclonal anti-pan-cytokeratin antibody (clone KL1, Immunotech, 




3.1. Expression of HERV-K protein as detected by immunohistochemistry 
To analyse the expression of the TM protein of HERV-K in the placenta, first of all the specificity of the 
polyclonal antibody was characterised. Goat serum 26 obtained after immunisation with the 
recombinant TM protein of HERV-K (Büscher et al., 2005), affinity-purified immunoglobulin from this 
serum, and the monoclonal antibody HERM-1811-5 were found to react with the recombinant TM 
protein in a Western blot analysis (not shown) and with specific epitopes using overlapping peptides 
corresponding to the TM protein (Fig. 1). Whereas the affinity purified antibodies from the polyclonal 
goat serum 26 recognised at least five different epitopes, the monoclonal antibody detected as 
expected only one epitope, IFEASK (Fig. 1). This epitope was also detected by the crude goat serum 
26, but not by the affinity-purified polyclonal antibody used herein. The latter recognised the epitopes 
ANQIND and NTSDFC. 
Using the affinity-purified antibodies, immunohistochemistry on paraffin-embedded placental tissue of 
different gestational time points was performed. The TM protein of HERV-K was found expressed in 
the villous (VT) and extravillous cytotrophoblast cells (EVT; Fig. 2). VT cells enveloping the whole 
villous stroma were HERV-K positive, while the outer syncytiotrophoblast layer, as well as the villous 
stroma, remained negative in the villi of early gestation placenta. This staining pattern was found in 
placental tissues throughout the first trimester of gestation (not shown). Both of the antibodies used 
showed the same staining pattern (Fig. 2A and B), albeit a higher intensity was found when the 
monoclonal HERM-1811-5 antibody was used (Fig. 2B). Negative controls with pre-immune serum 
(Fig. 2C) and isotype control antibodies (Fig. 2D) confirmed the specificity of the antibodies used. 
 
  
The cytotrophoblast cells in the villi of placental tissue were also positive for HERV-K around mid-
gestation, but with reduced staining compared with the first trimester (Fig. 2E). The positive staining 
was found in the remaining few VT cells of the term-placenta (Fig. 2F). The intensity of the staining in 
the positive cytotrophoblast cells did not change during pregnancy, indicating a strong and continuous 
expression of the TM protein of HERV-K in VT cells of all gestational ages. Expression was 
maintained in the columns of EVT cells (Fig. 2B) and in EVT cells invading the decidua (Fig. 2G). To 
characterise the invasive EVT within decidua, a serial section of the respective tissue sample was 
stained for cytokeratin (Fig. 2H, arrow). 
 
3.2. Expression of HERV-K protein as measured by Western blot analysis 
To confirm the immunohistochemical data and to characterise the expression of the TM protein of 
HERV-K in more detail, Western blot analyses were performed. Protein isolates were obtained from 
either frozen tissue of the placenta obtained at different weeks of gestation or from EVT cells by 
isolation of ErbB2-positive cells from the early pregnancy decidua. ErbB2, the human epidermal 
growth factor receptor 2, was found expressed on human EVT cells. To investigate the expression of 
the TM protein, both types of antibodies were used. The monoclonal antibody HERM-1811-5 detected 
HERV-K-specific proteins with a molecular weight of 26 kDa and 55 kDa (Fig. 3A), the affinity-purified 
goat antibodies detected mainly the 55 kDa protein (Fig. 3B). The purified recombinant TM protein of 
HERV-K and the teratocarcinoma cell line PA-1 were used as positive controls, HUVEC were used as 
negative controls. Whereas HERV-K-specific bands were detected in all placental samples tested by 
the purified antibodies, only very weak signals were obtained for the first trimester samples when the 
monoclonal antibody was used. Both antibodies did not detect any proteins in the negative control and 
the HUVEC cells. Thus, the TM protein seems to be expressed in the human placenta throughout the 
entire gestation. Pooled isolated EVT cells from two different samples of the decidua (gestational 
weeks 8 and 10) showed a clear expression of the TM protein of HERV-K. In addition, Western blot 
analysis of two trophoblast-derived choriocarcinoma cell lines, JEG and JAR, showed in a clear signal 




Here we show for the first time expression of the TM protein of HERV-K in villous cytotrophoblast (VT) 
and extravillous cytotrophoblast (EVT) cells, but not in the syncytiotrophoblast of the human placenta. 
As previously shown, syncytin-1 (HERV-W) is also localised in VT and EVT cells ( [Frendo et al., 
2003] and [Muir et al., 2006]), while syncytin-2 (HERV-FRD) is only expressed in VT cells (Malassiné 
et al., 2007). There is compelling evidence that syncytin-1 and syncytin-2 are involved in the 
generation of the syncytiotrophoblast and therefore play an important role in human reproduction ( 
[Blond et al., 2000] and [Mi et al., 2000]). Syncytin-like proteins have also been found in mice 
(syncytin-A, syncytin-B) that are homologous, but not orthologous to the human syncytins (Dupressoir 
et al., 2005). Knockout mice for the murine syncytin-A died in utero, indicating that this gene is 
essential for mouse embryonic development (Dupressoir et al., 2009). Endogenous retroviral env 
genes were also “enslaved” for placental functions in sheep (Black et al., 2010) and rabbits (Heidmann 
et al., 2009). In the sheep, the envelope gene of endogenous retroviruses related to the Jaagsiekte 
sheep retrovirus was shown to be involved in placenta evolution and inhibition of their expression by 
RNA interference compromised conceptus elongation. In the rabbit syncytin-Ory 1 is responsible for 
the formation of the syncytiotrophoblast. These data indicate that “enslavement” of retroviral genes 
must have occurred independently and on several occasions during mammalian evolution. 
 
4.1. HERV-K expression in placental tissue and in tumours 
To date, HERV-K expression has only been found in stem cell tumours (Löwer et al., 1996), 
melanomas ( [Muster et al., 2003], [Büscher et al., 2005] and [Büscher et al., 2006]) and trophoblast 
tumours (Herbst et al., 1996). The function of HERV-K during tumour development is still unclear. 
There is evidence that the accessory proteins Rec and Np9, encoded by different open reading frames 
in the env gene, might be involved in tumour development ( [Galli et al., 2005], [Boese et al., 
2000] and [Armbruester et al., 2002]). On the other hand, the expression of HERV-K in tumours may 
  
be a secondary event based on activated transcription factors during tumourigenesis. Due to their 
immunosuppressive properties expression of the retroviral TM protein on the tumour cells may provide 
protection from the immune system as shown in experimental mouse tumours models expressing 
different retroviral TM proteins ( [Mangeney and Heidmann, 1998], [Mangeney et al., 2001] and [Blaise 
et al., 2001]). 
Since villous cytotrophoblast cells were also expressing the HERV-K TM protein, whereas 
syncytiotrophoblast cells remained negative, it could be assumed that HERV-K has a fusogenic 
potential as well. Thus, a redundancy of function may allow compensation if one of the HERV genes is 
non-functional. This accounts for example for ENV-3, a gene expressed in the placenta, but which is 
not functional in 1% of fertile women (de Parseval and Heidmann, 1998). 
 
4.2. Potential immunosuppressive function of HERV-K in the placenta 
The adequate regulation of placenta development is temporally and spatially restricted. Inhibition of 
the trophoblast invasion may lead to diseases like preeclampsia; uncontrolled invasion may lead to 
placenta accreta, increta or even percreta ( [Knerr et al., 2002] and [Lavillette et al., 2002]). 
The suppression of the maternal immune system during pregnancy is unique, allowing the trophoblast 
to invade and protecting the embryo from immunological rejection, while inhibiting viral and bacterial 
infections at the same time. The fact that EVT cells expressing c-erbB2 are regularly found in intimate 
contact with maternal immune cells, suggests a potential relevance of HERV-K in the induction of the 
immunosuppression. Our findings that the TM protein of HERV-K has immunosuppressive properties 
that are very similar to those of the TM protein of HIV-1 and other retroviruses ( [Denner, 




In addition to the TM protein of the human endogenous retroviruses HERV-W (syncytin 1) and HERV-
FRD (syncytin 2), the TM protein of HERV-K is also expressed in the human placenta. It is of great 
interest for the understanding of the gestational process to learn the specific functions of all 
endogenous retroviruses expressed in the placenta and to analyse their interaction, if any. The fact 
that the placentas of different mammals differ significantly and that different species “enslaved” TM 
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Figure 1. Results of the epitope mapping of antibodies specific to the TM protein of HERV-K. The 
sequence of the entire TM protein gp36 is shown, the sequence of the recombinant protein used for 
immunisation is shown in black and the Cys-Cys-loop in bold. The epitopes recognised by the goat 
serum 26 (dark grey), the affinity-purified antibodies (light grey) and the monoclonal antibody (black) 




Figure 2. Immunohistochemical detection of the TM protein of HERV-K in formalin-fixed tissue of the 
human placenta and the decidua using the affinity purified antibodies from goat serum 26 (A) and the 
monoclonal HERM-1811-5 (B, E, F and G). In addition, the pre-immune serum from goat 26 (C), the 
monoclonal IgG isotype control antibody (D) and a pan-cytokeratin antibody (H) were used. The white 
head arrows mark the syncytiotrophoblast, the black arrows the villous trophoblasts (VT). (A) The 
affinity purified antibodies from goat serum 26 stained the villous cytotrophoblasts (VT, black-headed 
arrow) and did not stain the syncytiotrophoblasts (white-headed arrow) in the seventh gestational 
week placenta. (B) Immunohistochemistry using the monoclonal antibody HERM 1811-5 confirmed the 
staining of the VT cells and the absence of staining in the syncytiotrophoblast. Whereas syncytia (*) 
were negative, the VT columns starting to become extravillous trophoblast (EVT) (white-headed arrow) 
show strong expression of the TM protein of HERV-K. (C) Pre-immune goat serum 26 and (D) isotype 
control antibody corresponding to the mouse monoclonal antibody did not stain placental cells at the 
seventh gestational week. (E) In a 22-week placenta the VT still show strong HERV-K expression, 
while the syncytiotrophoblast cells were negative. (F) Villi of a mature placenta (gestational week 39) 
show only a few remaining VT cells positive for HERV-K. (G) In the early gestation (eighth week) 
decidua basalis the invasive EVT cells (arrows) are positive for HERV-K. (H) Serial section stained 
with cytokeratin to mark the EVT (arrows), * marks the endometrial gland. Magnification ×400 in all 
cases, the magnification bar represents 50 μm, brown: DAB, blue: counter stain with haematoxylin. 
  
Figure 3. Western blot analysis of placental tissues throughout pregnancy, weeks 6–39, HUVEC cells, 
isolated pooled extravillous cytotrophoblasts (EVT) from weeks 8 and 10, teratocarcinoma cell line PA-
1, the recombinant TM protein (TM), negative control (bovine serum albumin), as well as the 
choriocarcinoma cell lines JEG and JAR. (A) applying the mouse monoclonal antibody HERM-1811-5, 
(B) the affinity purified antibodies from goat antiserum 26 and (C) an antibody reactive with beta-actin. 
The recombinant HERV-K transmembrane envelope protein (TM) served as a positive control. 
 
